International Edition
Latest News
Health

Obesity Drug Pipeline Expands Beyond 200 Candidates as Market Surges Toward $92 Billion in 2026, Medscape Reports

More than 200 companies are now developing over 200 obesity therapies, including at least 30 in late-stage trials, as the global market surges toward a projected $92 billion in 2026, Medscape reported. The market reached $66 billion in…

More than 200 companies are now developing over 200 obesity therapies, including at least 30 in late-stage trials, as the global market surges toward a projected $92 billion in 2026, Medscape reported.

The market reached $66 billion in list-price sales in 2025 and could hit $105 billion to $200 billion by 2027, making obesity one of the world’s five most valuable therapeutic classes by 2030, according to data-analytics firm IQVIA. DelveInsight described the landscape as “robust” in an October 2026 analysis.

Beyond GLP‑1: new mechanisms crowd the field

AbbVie’s ABBV‑295, a long-acting amylin analog with a non-incretin mechanism, showed up to 9.8% weight loss at 12 weeks in a phase 1 trial presented at the European Association for the Study of Diabetes meeting in September. A phase 2 study enrolling about 360 adults with obesity or overweight plus one comorbidity is measuring percent body-weight change at week 32; preliminary results could arrive in the first half of 2027.

Amgen’s MariTide, a monthly peptide-antibody conjugate that activates the GLP‑1 receptor while antagonizing GIP, has completed enrollment in phase 3 studies for obstructive sleep apnea and cardiovascular outcomes. A head-to-head type 2 diabetes study versus semaglutide has begun, with two more trials starting in the fourth quarter of 2026. The first primary completions, MARITIME‑1 and ‑2, are estimated for 2027.

Farmacos antiobesidad apuntan nuevos usos como adicciones neurodegeneracion pero limitaciones acceso desigual
Photo: LaSexta

Pfizer is advancing two injectable candidates. Berobenatide (PF‑08653944), an ultra-long-acting GLP‑1 agonist, has roughly 10 phase 3 trials underway or starting, including VESPER‑4 and VESPER‑5 (weekly dosing) and VESPER‑6 (monthly dosing). The first primary endpoint readout from VESPER‑4 is expected in the third quarter of 2027.

A long-acting amylin analog, MET‑233i, is being tested in combination with berobenatide in a phase 1/2a study with data due in the second half of 2026, and in the phase 2b SOLIS‑1 trial, which has completed enrollment.

Roche and Zealand Pharma are co-developing petrelintide, a long-acting human amylin analog dosed weekly. The registrational ZUPREME phase 3 program — comprising ZUPREME‑3 (obesity/overweight without type 2 diabetes), ZUPREME‑4 (with type 2 diabetes) and ZUPREME‑5 (with established cardiovascular disease) — plans to enroll about 7,000 participants total.

A phase 2 combination study with Roche’s dual GLP‑1/GIP agonist enicepatide (CT‑388), called ZYNERGY, is slated for the second half of 2026. Phase 3 results from ZUPREME‑1 were recently published in The Lancet Diabetes & Endocrinology.

Viking Therapeutics’ dual GLP‑1/GIP agonist VK2735 is in phase 3 (VANQUISH) for the subcutaneous formulation and phase 3 (SUNRISE) for an oral version. The next milestone is completion of the VANQUISH trials, anticipated in 2027.

Lilly is moving the co-formulated EloraTZP (oralintide plus tirzepatide) toward phase 3 studies by late 2026 using an optimized titration scheme, while also exploring bimagrumab to preserve lean mass during weight loss. Novo Nordisk’s UBT251, a unimolecular GLP‑1/GIP/glucagon triple agonist licensed from United Laboratories, is in a new phase 2 trial of roughly 300 people with overweight or obesity and type 2 diabetes; results are expected by late 2027, according to Medscape.

Novel pathways: siRNA, adipocyte apoptosis, bitter-taste receptors

Alnylam’s ALN‑2232 (siRNA against ACVR1C) and ALN‑6222 (siRNA against INHBE) are in early trials, with initial phase 1 data for ALN‑2232 planned for a fourth-quarter earnings presentation. Caliway’s CBL‑514, a first-in-class injectable small molecule designed to induce adipocyte apoptosis, showed statistically significant reductions in both subcutaneous and visceral fat on MRI in phase 2.

Phase 3 trials SUPREME‑01 and ‑02 are recruiting, with topline data from SUPREME‑01 expected in the second half of 2027. The U.S. FDA has also authorized a phase 2 study of CBL-514 combined with tirzepatide in adults with overweight or obesity.

Aardvark Therapeutics’ ARD‑101, an oral bitter-taste receptor agonist combined with sitagliptin, had its U.S. clinical hold lifted in October. The phase 3 HERO trial and open-label extension for Prader-Willi syndrome hyperphagia concluded in June; the company plans to propose a new phase 3 design to the FDA and resume activities in 2027. Obesity-focused phase 2 trials POWER and STRENGTH remain on hold.

Despite the pipeline breadth, access remains concentrated in wealthy nations even though obesity and diabetes burdens are disproportionately higher in low- and middle-income countries, researchers from the London School of Economics and Brown University noted in a Science special issue. For much of Western Europe, generic entry is not expected until 2031-2032.

How large is the obesity drug market projected to be in 2026?
IQVIA projects $92 billion in global list-price sales for 2026, up from $66 billion in 2025.

AbbVie was formed in 2012 as a spin-off from Abbott Laboratories, taking its name from “Abbott” and “vie” — a Latin root meaning life. It became a public company in January 2013 and acquired Allergan for about $63 billion in 2019, a deal that required divesting several assets to gain regulatory approval. The company is now ranked sixth among biomedical firms by revenue and 77th on the Fortune 500.

Why is global access described as a fundamental challenge?
Kenneth Shadlen and Olivier Wouters wrote in Science that supply and pricing concentrate access in high-income countries despite the greater disease burden in low- and middle-income nations, with generic competition in Western Europe not expected until the early 2030s, according to LaSexta.

About the author: Health Desk

Health Desk at Archynewsy.